MedTrace Logo

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1018

Last updated 2026-05-20

No results posted yet for this study

Summary

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Conditions

  • Untreated Follicular Lymphoma

Interventions

DRUG

Surovatamig

a fully human bispecific monoclonal IgG4 antibody

DRUG

R-CHOP

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone

DRUG

R-CVP

Rituximab, Cyclophosphamide, Vincristine and Prednisone

DRUG

BR

Bendamustine, Rituximab

Sponsors & Collaborators

Principal Investigators

  • Chan Cheah, MBBS FRACP FRCPA DMSc · Sir Charles Gairdner Hospital (SCGH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-07
Primary Completion
2031-11-26
Completion
2031-11-26
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Czechia
  • Denmark
  • Finland
  • Hong Kong
  • Hungary
  • India
  • Japan
  • Poland
  • Puerto Rico
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549595 on ClinicalTrials.gov